Back To Search Results

Clin Assoc Prof Ho Yew Leng Aloysius

MBBS, MMed(Int Med), FRCP, FRCPath(UK)

Senior Consultant

Singapore General Hospital

Specialty: Haematology, Haematology

Sub-specialties: Haematopoietic Stem Cell ＆ Cellular Therapy, Acute Leukemia, Bone Marrow Failure Syndromes

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Aplastic Anaemia, Chronic lymphocytic leukemia, Chronic Myeloid Leukemia (CML), Deep Vein Thrombosis, Deep Vein Thrombosis, essential thrombocythemia, Multiple Myeloma, Myelodysplastic Syndromes, Myelofibrosis, Polycythemia Vera, Thalassaemia.

Clinical Appointments

Medical Director, Singapore Cord Blood Bank
Head ＆ Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
Director of Cell Transplant, SD Transplant Centre, Programme Director, Haematopoietic Stem Cell (Adult) & Umbilical Cord Transplant Programme and Senior Consultant SingHealth Duke-NUS Transplant Centre
Senior Consultant Haematology Singapore General Hospital
Senior Consultant National Cancer Centre Singapore

Profile

Dr Ho graduated with a Bachelor of Medicine and Surgery from the University of Adelaide and a Master of Medicine from the National University of Singapore. He is a Fellow of the Royal College of Physicians (London) and of the Royal College of Pathologists. He completed his training in Haematology at King’s College Hospital in London and was Consultant Haematologist in King’s before he joined SGH.

Dr Ho has an interest in haematopoietic stem cell transplantation, the myelodysplastic syndromes and other bone marrow failure syndromes and acute myeloid leukaemia.

Education

University of Adelaide, South Australia

Professional Appointments and Committee Memberships

Clinical Associate Professor Duke-NUS Graduate Medical School
Clinical Senior Lecturer, YLL School of Medicine
Director, Singhealth Duke-NUS Blood Cancer Centre
Medical Director, Singapore Cord Blood Bank
Lead, Haematopoietic Cell Therapy and Transplant Service, Singapore General Hospital, Singapore

Awards

Research Interests

Myelodysplastic Syndrome/Bone marrow failure syndromes
Haematopoietic Progenitor Cell Transplantation
Immune effector cell therapy

Publications

Kolla BC, Halim NAA, Cao Q, Sachs Z, Warlick E, Weisdorf D, et al. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature. Br J Haematol. 2021 Jul;194(1):140–4.
Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and　 differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2021 Aug;
Giebel S, Labopin M, Sobczyk-Kruszelnicka M, Stelljes M, Byrne JL, Fegueux N, et al. Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2021 Feb;56(2):481–91.
Pwint K-SW, Chen Y, Diong CP, Goh Y-T, Grant D, Ho A, et al. Mobilization kinetics of peripheral blood stem cells with rescue plerixafor -　real-world experience from a single center. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 1740–3.
Tan EK, Koh YX, Kee T, Juhari JB, Tan TE, Sim DKL, et al. Waitlisted Transplant Candidates’ Attitudes and Concerns Toward Transplantation　During COVID-19. Ann Transplant. 2020 Dec;25:e926992.
Prasath A, Ho A, Ng J, Lin P-Y, Yang K-L. Discovery of a novel HLA-A*02 variant, HLA-A*02:402, in a Singaporean cord blood unit. HLA. 2020 Aug;96(2):205–6.
Prata PH, Eikema D-J, Afansyev B, Bosman P, Smiers F, Diez-Martin JL, et al. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party. Bone Marrow Transplant. 2020 Jun;55(6):1050–8.
Quek J, Lee JJ, Lim FL, Diong C, Goh YT, Gopalakrishnan S, et al. Donor-type fresh frozen plasma is effective in preventing hemolytic reaction in major ABO incompatible allogeneic stem cell transplant. Transfusion. 2019 Jan;59(1):335–9.
Iida M, Kodera Y, Dodds A, Ho AYL, Nivison-Smith I, Akter MR, et al. Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the　second report from APBMT 2005-2015. Bone Marrow Transplant. 2019 Dec;54(12):1973–86.
Ong SY, Li S-T, Wong GC, Ho AYL, Nagarajan C, Ngeow J. Delayed diagnosis of Shwachman diamond syndrome with short telomeres and a review of　cases in Asia. Vol. 9, Leukemia research reports. 2018. p. 54–7.
Tan S, Takano A, Ho A, Tan KL. Asthmatic adult with marked blood eosinophilia: is it truly asthma? BMJ Case Rep. 2018 May;2018.
Belsey SL, Ireland R, Lang K, Kizilors A, Ho A, Mufti GJ, et al. Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men. Ther Drug Monit. 2017 Oct;39(5):499–504.
Wang L, Allen J, Diong C, Goh Y-T, Gopalakrishnan S, Ho A, et al. Respiratory virus infection after allogeneic hematopoietic stem cell transplant in a　tropical center: Predictive value of the immunodeficiency scoring index. Transpl Infect Dis. 2017 Jun;19(3).
Zhou W, Sultana R, Diong C, Goh Y-T, Gopalakrishnan S, Ho A, et al. Long-term renal outcome after allogeneic hemopoietic stem cell transplant: A comprehensive analysis of risk factors in an Asian patient population. Clin Transplant. 2017 Apr;31(4).
Phipps C, Ho AY, Linn YC, Gopalakrishnan S, Ang AL, Lee JJ, et al. Thirty Years of Bone Marrow Transplantation in the Singapore General Hospital. Ann Acad Med Singapore. 2016 Jul;45(7):315–7.
Ghosh A, Tan TT, Linn YC, Gopalakrishnan S, Goh YT, Hwang W, et al. What We Learned From Plasma BK-Virus Monitoring in Allogeneic Hematopoietic Transplant Recipients. Vol. 100, Transplantation. United States; 2016. p. e17-8.
Kumar R, Kimura F, Ahn KW, Hu Z-H, Kuwatsuka Y, Klein JP, et al. Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source　for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biol blood marrow Transplant J Am Soc Blood Marrow Transplant. 2016 May;22(5):932–40.
Ong S-Y, Truong H-T-T, Diong CP, Linn Y-C, Ho AY-L, Goh Y-T, et al. Use of Valacyclovir for the treatment of cytomegalovirus antigenemia after hematopoietic stem cell transplantation. BMC Hematol. 2015;15:8.
Lao Z, Yiu R, Wong GC, Ho A. Treatment of elderly patients with acute myeloid leukemia with azacitidine results　in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy. Asia Pac J Clin Oncol. 2015 Mar;11(1):54–61.
Ma L, Hao S, Diong C, Goh Y-T, Gopalakrishnan S, Ho A, et al. WPSS is a strong prognostic indicator for clinical outcome of allogeneic transplant for myelodysplastic syndrome in Southeast Asian patients. Ann Hematol. 2015 May;94(5):761–9.
Ma L, Hao S, Diong C, Goh Y-T, Gopalakrishnan S, Ho A, et al. Pre-transplant achievement of negativity in minimal residual disease and French-American-British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of Southeast Asian patients. Leuk Lymphoma. 2015 May;56(5):1362–9.
Potter VT, Krishnamurthy P, Barber LD, Lim Z, Kenyon M, Ireland RM, et al. Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. Biol blood marrow Transplant　J Am Soc Blood Marrow Transplant. 2014 Jan;20(1):111–7.
Kirwan M, Walne AJ, Plagnol V, Velangi M, Ho A, Hossain U, et al. Exome sequencing identifies autosomal-dominant SRP72 mutations associated with familial aplasia and myelodysplasia. Am J Hum Genet. 2012 May;90(5):888–92.
Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S, et al. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult　T-cell leukaemia/lymphoma (ATLL). Leuk Res. 2012 Jul;36(7):857–61.
Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011 Aug;118(8):2351–7.
Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in　relapsed advanced stage follicular lymphoma. Br J Haematol. 2008 Apr;141(2):235–43.
Gooneratne L, Nagi W, Lim Z, Ho AY, Devereux S, Pagliuca A, et al. Sarcoidosis and haematological malignancies: is there an association? Vol. 141, British journal of haematology. England; 2008. p. 260–2.
Creamer D, Martyn-Simmons CL, Osborne G, Kenyon M, Salisbury JR, Devereux S, et al. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy. Arch Dermatol. 2007 Sep;143(9):1157–62.
Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M, et al. Delayed attainment of full donor chimaerism following alemtuzumab-based　reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol. 2007 Aug;138(4):517–26.
Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AYL. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib　therapy. Vol. 137, British journal of haematology. England; 2007. p. 374–5.
Ramasamy K, Lim Z, Pagliuca A, Devereux S, Ho AYL, Mufti GJ. Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: report of three cases and review of literature. Leuk Lymphoma. 2007 Feb;48(2):290–4.
Lim Z, Pagliuca A, Simpson S, Cottam S, Ervine M, Ho AYL, et al. Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data. Br J Haematol. 2007 Feb;136(3):448–50.
Lim Z, Baker B, Zuckerman M, Wade JJ, Ceesay M, Ho AYL, et al. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. J Infect. 2007 Feb;54(2):e83-6.
Lim ZY, Ho AYL, Ingram W, Kenyon M, Pearce L, Czepulkowski B, et al. Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol. 2006 Oct;135(2):201–9.
Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2006 Nov;108(9):2928–36.
Chan L, Hardwick NR, Guinn B, Darling D, Gäken J, Galea-Lauri J, et al. An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother. 2006 Aug;55(8):1017–24.
Ho AYL, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for　myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004 Sep;104(6):1616–23.
Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004 Jan;103(2):428–34.
Mufti G, List AF, Gore SD, Ho AYL. Myelodysplastic syndrome. Hematol Am Soc Hematol Educ Progr. 2003;176–99.
Ho AYL, Deacon A, Osborne G, Mufti GJ. Precipitation of porphyria cutanea tarda by imatinib mesylate? Vol. 121, British journal of haematology. England; 2003. p. 375.
Ho AYL, Kenyon M, El-Hemaidi I, Devereux S, Pagliuca A, Mufti GJ. Reduced-intensity allogeneic hematopoietic stem cell transplantation with　alemtuzumab conditioning regimens: survival does not plateau until after day 200. Vol. 101, Blood. United States; 2003. p. 779–80.
Ho AYL, Pagliuca A. Is there a role for reduced-intensity haematopoietic stem cell transplantation for indolent non-Hodgkin’s lymphoma? Hematology. 2002 Dec;7(6):345–54.